We are live on ! Find out more
CEROW

CERo Therapeutics Warrants
CEROW

Delisted

CEROW was delisted on the 30th of October, 2025.

Back to rankings

41 hedge funds and large institutions have $3.7M invested in CERo Therapeutics Warrants in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

17% more funds holding

Funds holding: 35 → 41 (+6)

12% less capital invested

Capital invested by funds: $4.21M → $3.7M (-$509K)

Holders
41
Holders Change
+6
Holders Change %
+17.14%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
3
Reduced
1
Closed
3
Calls
$11K
Puts
–
Net Calls
+$11K
Net Calls Change
-$21K

Top Buyers

Rank Fund Capital Flow
1
CS
Clear Street
New York
+$53.7K
2
SRCM
Sage Rock Capital Management
New York
+$14.8K
3
AGM
Alpine Global Management
New York
+$8.88K
4
HIM
HGC Investment Management
Ontario, Canada
+$8.06K
5
SSA
Schonfeld Strategic Advisors
New York
+$5.8K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$71K
2
CL
CSS LLC
Illinois
-$19K
3
BI
Bulldog Investors
New Jersey
-$482
Name Holding Trade Value Shares
Change 		Change in
Stake
MP
1
Mangrove Partners
Connecticut
$1.64M – – –
RCM
2
Radcliffe Capital Management
Pennsylvania
$1.5M – – –
HCM
3
Highbridge Capital Management
New York
$88K – – –
MI
4
MMCAP International
Cayman Islands
$38K – – –
CF
5
Cantor Fitzgerald
New York
$36K – – –
CS
6
Clear Street
New York
$33K +$53.7K +333,118 New
PC
7
Periscope Capital
Ontario, Canada
$32K – – –
SCM
8
Saba Capital Management
New York
$31K – – –
PAMP
9
Polar Asset Management Partners
Ontario, Canada
$30K – – –
LA
10
Linden Advisors
New York
$27K – – –
AA
11
AQR Arbitrage
Connecticut
$25K – – –
ACM
12
Atalaya Capital Management
New York
$25K – – –
CCM
13
Context Capital Management
California
$20K – – –
QGA
14
Q Global Advisors
Texas
$17K – – –
HIM
15
HGC Investment Management
Ontario, Canada
$17K +$8.06K +50,000 +100%
FTCM
16
Fir Tree Capital Management
New York
$13K – – –
TI
17
Telemetry Investments
New York
$13K +$564 +3,500 +3%
Parallax Volatility Advisers
18
Parallax Volatility Advisers
California
$12K – – –
NAM
19
Nexpoint Asset Management
Texas
$11K – – –
CH
20
CVI Holdings
Delaware
$10K – – –
SRCM
21
Sage Rock Capital Management
New York
$9K +$14.8K +91,999 New
KPF
22
K2 Principal Fund
Ontario, Canada
$8K – – –
PMAM
23
Picton Mahoney Asset Management
Ontario, Canada
$8K – – –
WAM
24
Wolverine Asset Management
Illinois
$8K – – –
AGM
25
Alpine Global Management
New York
$6K +$8.88K +55,100 New
1
2

CEROW Hedge Fund Activity: Q2 2022 in Review

41 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q2 2022, worth a combined $3.7M — down 12% from $4.21M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CEROW positions and 3 closed out — a net gain of 6 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Clear Street, opening a new position worth an estimated $53.7K. The largest seller was Citadel Advisors, exiting entirely with an estimated $71K sold.

  • 41 institutional investors held CERo Therapeutics Warrants (CEROW) as of Q2 2022, up from 35 in Q1 2022.
  • Funds reported $3.7M of CERo Therapeutics Warrants stock for Q2 2022, down 12% quarter-over-quarter.
  • 9 funds opened new CERo Therapeutics Warrants positions in Q2 2022 and 3 closed out, a net change of +6 holders.
  • The largest CERo Therapeutics Warrants buyer in Q2 2022 was Clear Street, an estimated $53.7K added.
  • The largest CERo Therapeutics Warrants seller in Q2 2022 was Citadel Advisors, an estimated $71K sold.

Based on aggregated 13F filings for Q2 2022.